Protocols
ABBVIE-M13-833 Phase I OPEN TO ACCRUAL *
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies
COG-AALL1521 Phase II OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
COG-AALL1631 Phase III OPEN TO ACCRUAL *
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
COG-AALL1721 Phase II OPEN TO ACCRUAL
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
COG-AALL1732 Phase III OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
COG-AALL1821 Phase II OPEN TO ACCRUAL
AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >= 1 to < 31 Years Old with First Relapse
COG-AAML1831 Phase III OPEN TO ACCRUAL
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin GO to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
COG-AAML1921 Phase I/II OPEN TO ACCRUAL *
A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia
COG-ADVL1521 Phase II OPEN TO ACCRUAL *
A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
COG-ANHL1522 Phase II OPEN TO ACCRUAL *
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
IIT-TALANO-CART-ALL Phase I OPEN TO ACCRUAL
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
PBMTC-ONC1401 Phase II OPEN TO ACCRUAL
The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
PTCTC-ONC1701-ENDRAD Phase II OPEN TO ACCRUAL
A Phase II Pilot Trial to Estimate Survival after a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-acute Lymphoblastic Leukemia (ALL) Who are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
TACL-MARQIBO Phase I OPEN TO ACCRUAL *
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
TACL-ONYX-CFZ008 Phase I OPEN TO ACCRUAL
Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia